Drug Trial Radar · NCT04726592
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
323
Actual
Start
Jul 8, 2021
Primary completion
Apr 10, 2024
Study completion Apr 10, 2024
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of clorazepate in addition to the usual medication for treating migraine attack in the emergency room
Conditions
- Migraine
- Migraine Without Aura
- Migraine With Aura
- Headache
Interventions
Clorazepate DipotassiumDrug
Clorazepate Dipotassium : 20 mg intravenous injection
PlaceboDrug
Placebo IV
KetoprofenDrug
Ketoprofen 100 mg IV
MetoclopramideDrug
Metoclopramide 10 mg IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain reliefTime frame: 2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Lariboisière
Paris, Île-de-France Region, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.